Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

BACKGROUND: There is an unmet need for COVID-19 prevention in patient populations who have not mounted or are not expected to mount an adequate immune response to complete COVID-19 vaccination. We previously reported that a single subcutaneous 1200 mg dose of the monoclonal antibody combination casi...

Descripción completa

Detalles Bibliográficos
Autores principales: Herman, Gary A, O'Brien, Meagan P, Forleo-Neto, Eduardo, Sarkar, Neena, Isa, Flonza, Hou, Peijie, Chan, Kuo-Chen, Bar, Katharine J, Barnabas, Ruanne V, Barouch, Dan H, Cohen, Myron S, Hurt, Christopher B, Burwen, Dale R, Marovich, Mary A, Musser, Bret J, Davis, John D, Turner, Kenneth C, Mahmood, Adnan, Hooper, Andrea T, Hamilton, Jennifer D, Parrino, Janie, Subramaniam, Danise, Baum, Alina, Kyratsous, Christos A, DiCioccio, A Thomas, Stahl, Neil, Braunstein, Ned, Yancopoulos, George D, Weinreich, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255947/
https://www.ncbi.nlm.nih.gov/pubmed/35803290
http://dx.doi.org/10.1016/S1473-3099(22)00416-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255947/
https://www.ncbi.nlm.nih.gov/pubmed/35803290
http://dx.doi.org/10.1016/S1473-3099(22)00416-9

Ejemplares similares